Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Paton NI, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh HWL, Molton J, Mortera L, Naval S, Bakar ZA, Pang YK, Lum L, Lim TK, Cross GB, Lekurwale G, Choi H, Au V, Connolly J, Hibberd M, Green JA; Pascolizumab Tuberculosis Trial Team.
Paton NI, et al.
J Infect Dis. 2024 Sep 23;230(3):590-597. doi: 10.1093/infdis/jiae104.
J Infect Dis. 2024.
PMID: 38527849
Clinical Trial.